Zogenix epilepsy drug meets main goal in late-stage trial

Share this post

(Reuters) – Zogenix Inc’s experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, keeping it on track to request regulatory approval next year.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply